tapebrief
GILD · Q2 2025

GILD · Q3 2025 Earnings

Bullish

Gilead Sciences

Reported October 30, 2025

30-second summary

30-second take: Gilead delivered Q3 FY2025 revenue of $7.77B (+3% YoY) and non-GAAP EPS of $2.47, and raised the low end of FY2025 product sales guidance by $100M while lifting GAAP EPS guidance by $0.75 at the midpoint on operational execution plus favorable tax adjustments. The substantive news is operational: Yeztugo hit 75% covered lives ahead of schedule, Descovy grew 20% YoY (decelerating from Q2's 35% but still well above the long-term 8% assumption), and management guided full-year Yeztugo sales to ~$150M. The melting Veklury asset (-60% YoY to $277M) and a flat $1.0B FY guide imply a high bar for Q4, and CVS coverage remains unresolved.

Headline numbers

EPS

Q3 FY2025

$2.47

Revenue

Q3 FY2025

$7.77B

+3.0% YoY

Gross margin

Q3 FY2025

78.6%

Free cash flow

Q3 FY2025

$3.96B

Operating margin

Q3 FY2025

42.8%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$7.77B+3.0%$7.08B+9.7%
EPS$2.47—$2.01+22.9%
Gross margin78.6%—78.7%-10bps
Operating margin42.8%—34.9%+790bps
Free cash flow$3.96B—$0.72B+450.3%

Guidance

Gilead raised full-year FY2025 GAAP EPS guidance substantially (+$0.50–$0.70) while modestly raising revenue and non-GAAP EPS, reflecting operational execution and favorable prior-quarter adjustments.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Revenue
FY2025
$28.3 to $28.7 billion$28.4 to $28.7 billion+$0.1 billion at low endRaised
Diluted EPS (GAAP)
FY2025
$5.85 to $6.15$6.65 to $6.85+$0.50 to +$0.70Raised
Non-GAAP Diluted EPS
FY2025
$7.95 to $8.25$8.05 to $8.25+$0.10 at low endRaised

Reaffirmed unchanged this quarter: Product Sales Excluding Veklury ($27.4 to $27.7 billion), Veklury ($1.0 billion)

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
HIV$5.277B+4.0%
Liver Disease$0.819B+12.0%
Oncology$0.788B-3.0%
Biktarvy$3.686B+6.0%
Descovy$0.701B+20.0%
Veklury$0.277B-60.0%
Cell Therapy$0.432B-11.0%
Trodelvy$0.357B+7.0%
Product sales excluding Veklury$7.068 billion—
Product sales excluding Veklury YoY growth4%—

Other KPIs

Q3 FY2025
SegmentQ3 FY2025
Non-GAAP product gross margin86.5%
Non-GAAP operating margin50.5%
Operating cash flow Q3$4.109 billion
R&D expenses as % of revenues17.3%
SG&A expenses as % of revenues17.5%
Cash and equivalents$9.4 billion

Management tone

No earnings call transcript was available for this print; tone analysis is limited to the press release and Q&A extracts. Multi-quarter narrative arc treated qualitatively below.

Q2 anchor → Q3 anchor: "milestone launch" → "ramp execution." Last quarter Yeztugo was framed as a generational moment ("bend the arc of the epidemic"); this quarter the language shifted to operational sequencing. Management told Chris Schott of JPMorgan to expect "gradual ramp, not step function" into Q4 despite hitting the 75% access bar ahead of schedule, citing the time required for practice integration and J-code workflow updates. This is the right framing — the 6-week euphoria of Q2 has matured into a more disciplined expectations-setting posture.

Pipeline framing escalated again. The new press-release language — "strongest clinical pipeline in Gilead's history, and no major loss of exclusivity expected until 2036" — extends the Q2 platform reframing further out. The 2036 LOE anchor is a deliberate signal to investors who have priced in a near-term patent cliff narrative. Pair this with the Q&A emphasis on "multiple potential product launches in 2026" and the strategic story is now explicitly long-duration.

Policy posture became proactive rather than defensive. Asked by Bernstein's Courtney Breen about MFN/Medicaid risk — the same topic management dodged at Q2 — the answer this quarter pivoted to a credentialing argument: 80% of IP in the US, 90% of taxes paid domestically, ~100% of R&D infrastructure US-based, $32B committed US investment. Management still declined to quantify downside but the framing has shifted from deflection to positioning. The PEPFAR lenacapavir partnership (2M people, 3 years, low-income countries) is now a talking point on policy alignment, not just a humanitarian footnote.

Q&A highlights

Jeff Meacham · Citigroup

What is the sourcing mix for Yes2Go patients (switches vs. new-to-market), and what demand drivers could provide momentum into 2026?

Yes2Go sourcing is mixed across switches (long-acting injectables, branded orals like Descovy, and generics) and new patients expected to grow over time. Management expects continued growth as market awareness increases and naive patient population expands. Full-year 2025 Yes2Go sales projected at approximately $150M.

Yes2Go sourcing across LAI, branded oral, and generic productsBalance of switches expected to continue with naive patient growth over timeFull-year 2025 Yes2Go sales guidance: ~$150MMarket awareness expected to drive naive patient adoption

Chris Schott · JPMorgan

How should Yes2Go sales evolve in Q4 and into 2026—gradual acceleration or step function, given recent 75% coverage achievement?

Management expects gradual ramp, not step function. Recent access wins occurred in final weeks of Q3 and require practice integration time. J-code implementation (Jan 1) could drive acceleration. 75% coverage was achieved ahead of schedule but will take time to monetize as practices update workflows.

Gradual ramp expected, not step changeRecent access wins in final weeks of Q3J-code activation on October 1st and January 1st updatesPractice integration required before sales acceleration

Salveen Richter · Goldman Sachs

What was the inventory impact for Yes2Go in Q3, and how are CVS pricing discussions progressing?

No inventory buy-in occurred in Q3; $15M stocking happened in late June and pulled through early Q3. Q3 $39M represents true demand. CVS and remaining 25% of payers are in ongoing discussions; management confident in reaching 90% coverage goal by end of H1 2026.

No Q3 inventory; Q3 $39M is true demand$15M stocking occurred in late June, pulled through in early Q375% access achieved ahead of scheduleTarget: 90% coverage by end of H1 2026

Courtney Breen · Bernstein

In context of White House drug pricing deals and higher Medicaid exposure, what flexibility and scale of impact mitigation is Gilead preparing for, compared to Part D redesign impact?

Management described ongoing constructive dialogue with administration focused on maintaining U.S. innovation incentives while addressing patient out-of-pocket costs and international pricing. Highlighted Gilead's unique position with 80% U.S. IP, 90% U.S. tax payments, 100% U.S. R&D infrastructure, and $32B U.S. investment commitment. Referenced PEPFAR lenacapavir partnership as example of constructive engagement.

Ongoing constructive engagement with administration80% of IP recognized in United States90% of taxes paid in U.S.Nearly 100% of R&D capital infrastructure in U.S.

Answers to last quarter's watch list

Yeztugo access ramp — Resolved positively. Management confirmed 75% access achieved ahead of schedule, with 90% targeted by end of H1 2026. Q3 Yeztugo revenue of $39M represents true demand (no inventory). However, management explicitly cooled expectations for a step-function Q4 — expect gradual ramp tied to practice workflow integration. Status: Resolved positively
Descovy growth sustainability — Resolved positively but with deceleration. Descovy grew 20% YoY in Q3, down from 35% in Q2 — still 2.5x the long-term 8% assumption, with PrEP-specific growth over 30%. Yeztugo cannibalization is occurring as predicted but Descovy continues to outgrow the historical baseline. Status: Resolved positively
HIV ex-Part D growth disclosure — Resolved positively. Management quantified underlying HIV growth ex-Part D at 8-9% versus the 4% reported number, the cleanest reconciliation yet of headwind vs. underlying demand. Status: Resolved positively
MFN/Medicaid policy clarity — Continue monitoring. Management offered a more developed framing (US IP, tax, R&D, and investment footprint) but again declined to quantify downside scenarios. The policy story is becoming more articulate but no scenario analysis was disclosed. Status: Continue monitoring
4182-1720 clinical hold resolution — Continue monitoring. No specific update on a replacement molecule or restart timeline appeared in the press release or Q&A captured. Silence on this is the second consecutive quarter without resolution. Status: Continue monitoring
Trodelvy first-line TNBC regulatory path — Continue monitoring. Management cited "positive data for Trodelvy in 1L metastatic triple negative breast cancer" but did not disclose sBLA filing timing. Trodelvy revenue grew 7% YoY in Q3, below the Q2 +14% pace. Status: Continue monitoring

What to watch into next quarter

Yeztugo Q4 trajectory vs. the ~$150M FY guide. Implied Q4 is ~$96M against $39M in Q3. Anything below $70M would suggest the J-code activation tailwind is weaker than management telegraphed; anything above $110M validates the gradual-but-steady framing.

Veklury Q4 print vs. the $1.0B FY reaffirmation. Implied Q4 is ~$240M against $277M in Q3 — flat-to-slightly-down sequentially, which contradicts the -60% YoY trajectory. A Q4 miss here would force a downward revision early in FY2026 framing.

CVS pricing resolution. Most evasive topic on the call. Any disclosed agreement (or explicit deferral) by Q4 FY2025 would move the 90% access target's credibility materially.

HIV ex-Part D bridge for FY2026. Management has now twice given underlying growth (>7% in Q2, 8-9% in Q3). Whether they frame 2026 HIV growth using the underlying number rather than reported will signal confidence in lapping the Part D headwind cleanly.

4182-1720 / WONDER program replacement molecule. Two consecutive quarters of silence is now a tell. Disclosure of an alternative compound and restart timeline at Q4 would close the loop; continued silence will start to read as a discontinuation in slow motion.

2026 launch slate specifics. Management cited "multiple potential product launches in 2026" as a centerpiece of the long-duration thesis. Watch for a Q4 or JPM Healthcare Conference disclosure that names the specific assets and timing — without it, the framing is rhetoric, not pipeline.

Sources

  1. Gilead Sciences Q3 FY2025 press release and financial tables (SEC EDGAR exhibit 99.1), 2025-10-30: https://www.sec.gov/Archives/edgar/data/882095/000088209525000044/exhibit991earningspressrel.htm
  2. Gilead Sciences Q3 FY2025 Q&A exchanges (as captured in extraction inputs)
  3. Gilead Sciences Q2 FY2025 Tapebrief, 2025-08-07 (prior-quarter watch list and guidance baseline)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.